Concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer show distinct genomic and immunological profiles suggestive of therapeutic strategies | Caris Life Sciences
Portal
Order

MI Cancer Seek™ is now available for clinical ordering. Learn more.

Home / Research / Publications / Concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer show distinct genomic and immunological profiles suggestive of therapeutic strategies

Publications

Back

Concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer show distinct genomic and immunological profiles suggestive of therapeutic strategies

– Caris Life Sciences

Poster

Key Finding:

  • Bladder carcinomas with concurrent truncating mutations in RB1 and CDKN1A have a distinct immunological profile and are enriched for mutations associated with benefit from inhibition of Chk1/Wee1, PARP, and immune checkpoint proteins. 
Read the Full Manuscript Download Publication

Discover
More

  • Structurally-oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes 

    – Caris Life Sciences

    Manuscript

    Abstract Purpose: 10-15% of prostate cancers (PCa) harbor recurrent FOXA1 aberrations whereby the alteration type and the effect on the forkhead( FKH) domain impacts protein-function. We developed… […]

  • Spliceosome Mutations in Metastatic Breast Cancer An Analysis of a Decentralized Clinical Trial and Large Clinical Genomic Dataset

    – Caris Life Sciences

    Poster

    […]
Learn More

Ready to Get Started on the Journey?

Name(Required)